Form 4: Ultragenyx EVP Crombez Reports Stock Transactions

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

Summary

• Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2025, Crombez acquired 16,813 shares of common stock through Restricted Stock Units (RSUs) and 14,971 shares through the conversion of performance stock units.
• Also on March 1, 2025, Crombez was granted stock options for 30,246 shares.
• On March 3, 2025, Crombez sold 8,945 shares of common stock at an average price of $42.10 to cover tax withholdings related to the vesting of RSUs.
• Following these transactions, Crombez beneficially owns 71,922 shares of common stock and stock options for 30,246 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of normal executive compensation and tax obligations. There is no indication of unusual activity or concern.

Positives

• The acquisition of shares through RSUs and performance stock units indicates confidence in the company's future performance.
• The granting of stock options incentivizes the executive to further contribute to the company's success.

Negatives

• The sale of shares to cover tax withholdings, while common, slightly reduces the executive's stake in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.

Key Dates